Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Therapy entities : Avrobio, inc. save search
AVROBIO Announces Agreement to Sell Cystinosis Gene Therapy Program for $87.5 Million
Published: 2023-05-22 (Crawled : 12:00) - biospace.com/
AVRO | $1.205 -2.82% -2.9% 39K
|
Health Technology
|
| O: 83.2%
H: 19.72%
C: -7.75%
program agreement therapy
AVROBIO Announces Positive Data from Phase 1/2 Clinical Trial of Investigational Gene Therapy for Cystinosis at the ASGCT 26th Annual Meeting
Published: 2023-05-18 (Crawled : 12:00) - biospace.com/
AVRO | $1.205 -2.82% -2.9% 39K
|
Health Technology
|
| O: 11.02%
H: 37.14%
C: 30.9%
positive meeting trial therapy
AVROBIO to Present Clinical and Preclinical Data from Lysosomal Disorder Gene Therapy Pipeline at WORLDSymposium™ 2023
Published: 2023-02-09 (Crawled : 13:00) - biospace.com/
AVRO | $1.205 -2.82% -2.9% 39K
|
Health Technology
|
| O: -4.73%
H: 14.29%
C: 13.04%
preclinical therapy pipeline
AVROBIO Announces New Positive Clinical Data and Outlines Clinical Development Plan Following Regulatory Discussions for its Gaucher Disease Gene Therapy
Published: 2022-12-07 (Crawled : 13:00) - biospace.com/
AVRO | $1.205 -2.82% -2.9% 39K
|
Health Technology
|
| O: 7.13%
H: 6.67%
C: -13.16%
disease positive therapy
AVROBIO Receives Rare Pediatric Disease Designation from the U.S. FDA for First-in-Class Gene Therapy for Gaucher Disease
Published: 2022-10-27 (Crawled : 12:00) - biospace.com/
AVRO | $1.205 -2.82% -2.9% 39K
|
Health Technology
|
| O: 3.94%
H: 2.96%
C: -5.26%
fda rare designation disease therapy
AVROBIO Announces Completion of Patient Dosing in First Gene Therapy Clinical Trial for Cystinosis
Published: 2022-10-25 (Crawled : 12:00) - biospace.com/
AVRO | $1.205 -2.82% -2.9% 39K
|
Health Technology
|
| O: -1.49%
H: 3.06%
C: 1.35%
trial therapy
AVROBIO Granted ILAP Designation from U.K. MHRA for First-in-Class Gene Therapy for Gaucher Disease
Published: 2022-10-18 (Crawled : 12:00) - biospace.com/
AVRO | $1.205 -2.82% -2.9% 39K
|
Health Technology
|
| O: 5.75%
H: 13.69%
C: 6.26%
designation disease granted therapy
AVROBIO Receives Rare Pediatric Disease Designation from U.S. Food and Drug Administration (FDA) for First Gene Therapy in Development for Cystinosis
Published: 2022-09-20 (Crawled : 12:00) - biospace.com/
AVRO | $1.205 -2.82% -2.9% 39K
|
Health Technology
|
| O: 1.31%
H: 2.53%
C: -4.61%
rare designation drug disease food therapy
AVROBIO Announces Neuronopathic Mucopolysaccharidosis Type II (nMPS-II) or Hunter Syndrome Clinical Trial Application (CTA) Accepted by U.K. Regulatory Agency to Initiate Pediatric Phase 1/2 Gene Therapy Trial
Published: 2022-09-14 (Crawled : 12:00) - biospace.com/
AVRO | $1.205 -2.82% -2.9% 39K
|
Health Technology
|
| O: 6.65%
H: 0.0%
C: -7.39%
application trial therapy
AVROBIO Receives Orphan Drug Designation from the U.S. Food and Drug Administration for AVR-RD-05, a Gene Therapy for Mucopolysaccharidosis Type II (MPSII) or Hunter Syndrome
Published: 2022-07-13 (Crawled : 12:00) - biospace.com/
AVRO | $1.205 -2.82% -2.9% 39K
|
Health Technology
|
| O: 2.37%
H: 3.08%
C: -1.22%
rd-05 designation drug food therapy avr-rd-05 mps-ih
AVROBIO Announces Preclinical Gene Therapy Data for Pompe Disease at American Society of Gene and Cell Therapy (ASGCT) Annual Meeting
Published: 2022-05-18 (Crawled : 12:00) - biospace.com/
AVRO | $1.205 -2.82% -2.9% 39K
|
Health Technology
|
| O: -3.53%
H: 1.24%
C: -8.07%
disease preclinical therapy pre-clinical avr-rd-03
AVROBIO Reports Positive Data From Phase 1/2 Clinical Trial of Investigational Gene Therapy for Cystinosis, Including New Interim Data on Neurocognitive Measures
Published: 2022-05-17 (Crawled : 12:20) - biospace.com/
AVRO | $1.205 -2.82% -2.9% 39K
|
Health Technology
|
| O: 8.51%
H: 0.0%
C: 0.0%
trial positive therapy phase 1
Moving gene therapy forward: Predictions for the next phase of development
Published: 2022-03-22 (Crawled : 14:00) - avrobio.com
AVRO | $1.205 -2.82% -2.9% 39K
|
Health Technology
|
| O: 0.0%
H: 5.38%
C: 2.53%
therapy
AVROBIO Reports Interim Data from Phase 1/2 Clinical Trial of Investigational Gene Therapy for Cystinosis
Published: 2022-02-09 (Crawled : 13:00) - biospace.com/
AVRO | $1.205 -2.82% -2.9% 39K
|
Health Technology
|
| O: 1.1%
H: 0.0%
C: -10.33%
gene therapy trial phase 1 report therapy kidney phase 2 phase 3
A periscope for gene therapy: How high-resolution methods like single-cell sequencing may help predict the fate of gene therapy drug product
Published: 2022-02-07 (Crawled : 20:00) - avrobio.com
AVRO | $1.205 -2.82% -2.9% 39K
|
Health Technology
|
| O: 0.55%
H: 0.0%
C: 0.0%
gene therapy drug cel therapy
The CMO Dating Game: Gene Therapy Edition
Published: 2022-01-20 (Crawled : 20:00) - avrobio.com
AVRO | $1.205 -2.82% -2.9% 39K
|
Health Technology
|
| O: -1.08%
H: 1.64%
C: -0.54%
gene therapy dating therapy cmo
Jasper Therapeutics Announces Research Collaboration with AVROBIO to Evaluate JSP191 as Conditioning Agent in Clinical Studies of Ex Vivo Lentiviral Gene Therapy
Published: 2021-11-09 (Crawled : 19:00) - biospace.com/
JSPR | $21.61 -6.89% -7.4% 65K
|
|
| O: -2.22%
H: 0.0%
C: 0.0%
AVRO | $1.205 -2.82% -2.9% 39K
|
Health Technology
|
| O: -1.63%
H: 0.5%
C: -3.64%
gene therapy therapy collaboration research
AVROBIO Receives Rare Pediatric Disease Designation from the U.S. FDA for AVR-RD-05, a Gene Therapy for Mucopolysaccharidosis Type II (MPSII) or Hunter Syndrome
Published: 2021-11-03 (Crawled : 12:00) - biospace.com/
AVRO | $1.205 -2.82% -2.9% 39K
|
Health Technology
|
| O: 2.99%
H: 0.0%
C: 0.0%
disease fda rare pediatric disease designation gene therapy therapy syndros designation rare avr-rd-05 rd-05 mps-ih
AVROBIO Reports New Interim Safety Data Across Investigational Gene Therapies for Fabry and Gaucher Disease Type 1
Published: 2021-10-19 (Crawled : 12:00) - biospace.com/
AVRO | $1.205 -2.82% -2.9% 39K
|
Health Technology
|
| O: 0.54%
H: 3.66%
C: 1.25%
disease gene therapies gene therapy therapy
FDA and the CMC goalposts: CMC should accelerate, not curb, gene therapy progress
Published: 2021-07-06 (Crawled : 17:00) - avrobio.com
AVRO | $1.205 -2.82% -2.9% 39K
|
Health Technology
|
| O: 1.01%
H: 1.44%
C: -5.87%
fda gene therapy therapy gene therapies
Gainers vs Losers
| 67% | 33% |
Top 10 Gainers
AGBA | News | $1.26 215.0% 68.25% 130M
|
Finance
EGOX | $0.0515 43.06% 30.1% 330M
|
OLB 4 | $0.33 -14.95% 25.53% 840K
|
Technology Services
NVFY | $2.77 31.28% 23.83% 33M
|
Consumer Durables
ZCMD | $1.87 28.97% 22.46% 31M
|
Commercial Services
RCON | $0.1112 13.01% 21.28% 1.7M
|
Distribution Services
INSG | $3.03 25.21% 20.13% 330K
|
Electronic Technology
GCTK | $0.8191 22.25% 18.2% 190K
|
Manufacturing
WLGS | $0.59 18.0% 17.9% 2.3M
|
ASNS | $0.828 21.75% 17.86% 18K
|
Your saved searches
Save your searches and get alerts when important news are released.